Anti-HIV agents at ICAAC.
Smart
T
T
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D018791:CD4 Lymphocyte Count / Q000187:drug effects*; D000077404:Cidofovir; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D003596:Cytosine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives; D004352:Drug Resistance, Microbial / Q000235:genetics; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007546:Isoquinolines; D007668:Kidney / Q000473:pathology; D009154:Mutation; D019888:Nelfinavir; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019258:Saquinavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013451:Sulfonic Acids; D017211:Treatment Failure; D019562:Viral Load
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D013451:Sulfonic Acids; D003596:Cytosine; D019888:Nelfinavir; D000077404:Cidofovir; D019258:Saquinavir; D019438:Ritonavir